{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T22:44:06Z","timestamp":1784241846125,"version":"3.55.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004735","name":"Hunan Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["2023JJ30822"],"award-info":[{"award-number":["2023JJ30822"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Hunan Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["2025JJ60530"],"award-info":[{"award-number":["2025JJ60530"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011790","name":"Xiangya Hospital, Central South University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011790","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018597","name":"Ministry of Education of the People's Republic of China Cultivation Fund of the Key Scientific and Technical Innovation Project","doi-asserted-by":"publisher","award":["YX202110"],"award-info":[{"award-number":["YX202110"]}],"id":[{"id":"10.13039\/501100018597","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.msard.2026.107158","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T17:19:53Z","timestamp":1774286393000},"page":"107158","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Ocular toxicity associated with anti-CD20 monoclonal antibodies: A pharmacovigilance analysis using the FAERS database"],"prefix":"10.1016","volume":"109","author":[{"given":"Yun","family":"Kuang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaxin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinlian","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longjian","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junlong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxia","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoping","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengxian","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.msard.2026.107158_bib0008","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1080\/13543784.2018.1459560","article-title":"Ublituximab for the treatment of CD20 positive B-cell malignancies","volume":"27","author":"Babiker","year":"2018","journal-title":"Expert. Opin. Investig. Drugs"},{"issue":"6","key":"10.1016\/j.msard.2026.107158_bib0012","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/pds.1742","article-title":"Quantitative signal detection using spontaneous ADR reporting","volume":"18","author":"Bate","year":"2009","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.msard.2026.107158_bib0022","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13256-015-0534-7","article-title":"Bilateral uveitis and Usher syndrome: a case report","volume":"9","author":"Benson","year":"2015","journal-title":"J. Med. Case Rep."},{"issue":"8","key":"10.1016\/j.msard.2026.107158_bib0020","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s40263-021-00842-9","article-title":"The disease-modifying therapies of relapsing-remitting multiple sclerosis and liver injury: A narrative review","volume":"35","author":"Biolato","year":"2021","journal-title":"CNS. Drugs"},{"key":"10.1016\/j.msard.2026.107158_bib0023","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.661882","article-title":"Rituximab in multiple sclerosis: are we ready for regulatory approval?","volume":"12","author":"Brancati","year":"2021","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.msard.2026.107158_bib0001","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1007\/s00415-023-12007-3","article-title":"Key characteristics of anti-CD20 monoclonal antibodies and clinical implications for multiple sclerosis treatment","volume":"271","author":"Delgado","year":"2024","journal-title":"J. Neurol."},{"issue":"9","key":"10.1016\/j.msard.2026.107158_bib0004","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1080\/14712598.2018.1508444","article-title":"The latest developments with anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia","volume":"18","author":"Evers","year":"2018","journal-title":"Expert. Opin. Biol. Ther."},{"issue":"2","key":"10.1016\/j.msard.2026.107158_bib0010","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1182\/blood-2015-06-651125","article-title":"Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial","volume":"127","author":"Fischer","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.msard.2026.107158_bib0013","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1383212","article-title":"Hepatitis-related adverse events associated with immune checkpoint inhibitors in cancer patients: an observational, retrospective, pharmacovigilance study using the FAERS database","volume":"15","author":"Fu","year":"2024","journal-title":"Front. Pharmacol."},{"issue":"15","key":"10.1016\/j.msard.2026.107158_bib0007","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1056\/NEJMoa2410965","article-title":"Efficacy and safety of Obinutuzumab in active Lupus nephritis","volume":"392","author":"Furie","year":"2025","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.msard.2026.107158_bib0024","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1038\/clpt.2012.50","article-title":"Novel data-mining methodologies for adverse drug event discovery and analysis","volume":"91","author":"Harpaz","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"issue":"9","key":"10.1016\/j.msard.2026.107158_bib0019","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.ctrv.2015.07.003","article-title":"Obinutuzumab in hematologic malignancies: lessons learned to date","volume":"41","author":"Illidge","year":"2015","journal-title":"Cancer Treat. Rev."},{"issue":"1","key":"10.1016\/j.msard.2026.107158_bib0006","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s40265-021-01650-7","article-title":"Ofatumumab: A review in relapsing forms of multiple sclerosis","volume":"82","author":"Kang","year":"2022","journal-title":"Drugs"},{"issue":"7-8","key":"10.1016\/j.msard.2026.107158_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2024.103588","article-title":"Rituximab-induced cystoid macular edema in a patient with systemic lupus erythematosus: A case report and literature review","volume":"23","author":"Lobo-Antu\u00f1a","year":"2024","journal-title":"Autoimmun. Rev."},{"issue":"10","key":"10.1016\/j.msard.2026.107158_bib0021","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1200\/JCO.1997.15.10.3266","article-title":"IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma","volume":"15","author":"Maloney","year":"1997","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.msard.2026.107158_bib0015","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1046\/j.1365-2125.2003.02007.x","article-title":"Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications","volume":"57","author":"Mangoni","year":"2004","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.msard.2026.107158_bib0003","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1007\/s00415-021-10744-x","article-title":"Anti-CD20 therapies for multiple sclerosis: current status and future perspectives","volume":"269","author":"Margoni","year":"2022","journal-title":"J. Neurol."},{"issue":"3","key":"10.1016\/j.msard.2026.107158_bib0009","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus Placebo in primary progressive Multiple sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.msard.2026.107158_bib0018","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/ane.13291","article-title":"Efficacy and safety of rituximab in autoimmune encephalitis: A meta-analysis","volume":"142","author":"Nepal","year":"2020","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.msard.2026.107158_bib0002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.biologicals.2020.11.002","article-title":"Anti-CD20 monoclonal antibodies in Systemic Lupus Erythematosus","volume":"69","author":"Shah","year":"2021","journal-title":"Biologicals"},{"issue":"47","key":"10.1016\/j.msard.2026.107158_bib0005","doi-asserted-by":"crossref","first-page":"7359","DOI":"10.1038\/sj.onc.1206939","article-title":"Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance","volume":"22","author":"Smith","year":"2003","journal-title":"Oncogene"},{"issue":"7","key":"10.1016\/j.msard.2026.107158_bib0017","first-page":"682","article-title":"Serious adverse drug events reported to the FDA: analysis of the FDA adverse event Reporting System 2006-2014 database","volume":"24","author":"Sonawane","year":"2018","journal-title":"J. Manage Care Spec. Pharm."},{"issue":"3","key":"10.1016\/j.msard.2026.107158_bib0016","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jtos.2017.05.003","article-title":"TFOS DEWS II Epidemiology Report","volume":"15","author":"Stapleton","year":"2017","journal-title":"Ocul. Surf."},{"issue":"1","key":"10.1016\/j.msard.2026.107158_bib0014","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13293-020-00308-5","article-title":"Sex differences in pharmacokinetics predict adverse drug reactions in women","volume":"11","author":"Zucker","year":"2020","journal-title":"Biol. Sex. Differ."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482600194X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482600194X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T12:26:10Z","timestamp":1781526370000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221103482600194X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":24,"alternative-id":["S221103482600194X"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2026.107158","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ocular toxicity associated with anti-CD20 monoclonal antibodies: A pharmacovigilance analysis using the FAERS database","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2026.107158","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107158"}}